Neptune to Hold Conference Call to Discuss Fourth Quarter and Fiscal Year Results
2015年5月7日 - 9:44PM
Neptune Technologies & Bioressources Inc. ("Neptune" or the
"Corporation") (Nasdaq:NEPT) (TSX:NTB), announced today that it
will be holding a conference call on Thursday May 28, 2015 at 9:00
AM (ET) to discuss its results for the fourth quarter and fiscal
year ended February 28, 2015.
The fourth quarter and fiscal year results press release will be
issued after markets close on May 27, 2015.
Conference Call Details:
Date: |
Thursday May 28, 2015 |
Time: |
9:00 AM Eastern Time |
Conference ID: |
42232164 |
Call: |
1‐877-380-5664 (within Canada & the
U.S.) |
|
1-631-813-4882 (Outside Canada and the
U.S.) |
|
(Please dial in 15 minutes before the
call begins) |
|
|
Webcast: |
A live audio webcast can be accessed
at: |
|
http://neptunekrilloil.com/investors/investor-events-and-presentations/ |
An archived recording of the conference call will also be
available on Neptune's website shortly after the call.
About Neptune Technologies & Bioressources
Inc.
Neptune is a biotechnology company engaged primarily in the
development and commercialization of marine-derived omega-3
polyunsaturated fatty acids (''PUFAs''). Neptune has a patented
process of extracting oils from Antarctic krill, and principally
sells omega-3 PUFAs as bulk oil to Neptune's distributors who
commercialize them under their private label primarily in the U.S.,
European and Australian nutraceutical markets. Neptune's
products generally come in bulk oil or capsule form and serve as a
dietary supplement to consumers. Neptune's head office is located
at 545 Promenade du Centropolis, Suite 100, Laval, Quebec.
Through its subsidiary Acasti Pharma Inc. ("Acasti"), in which
Neptune holds approximately 48% of the participating and voting
rights, Neptune is also pursuing opportunities in the medical food
and prescription drug markets. Acasti focuses on the research and
development of safe and therapeutically effective compounds for
highly prevalent atherosclerotic conditions, such as
cardiometabolic disorders and cardiovascular diseases. Its lead
prescription drug candidate is CaPre®, a purified high omega-3
phospholipid concentrate derived from Neptune krill oil being
developed to address the prevention and treatment of
cardiometabolic disorders, including hypertriglyceridemia, which is
characterized by abnormally high levels of triglycerides.
Forward Looking Statements
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking statements"
within the meaning of the U.S. securities laws and Canadian
securities laws. Such forward-looking statements involve known and
unknown risks, uncertainties, and other unknown factors that could
cause the actual results of Neptune to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are
urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or "plans"
to be uncertain and forward-looking. Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date of this press release.
The forward-looking statements contained in this news release
are expressly qualified in their entirety by this cautionary
statement and the "Cautionary Note Regarding Forward-Looking
Information" section contained in Neptune's latest Annual
Information Form, which also forms part of Neptune's latest annual
report on Form 40-F, and which is available on SEDAR at
www.sedar.com, on EDGAR at www.sec.gov/edgar.shtml and on the
investor section of Neptune's website at www.neptunebiotech.com
(the "AIF"). All forward-looking statements in this press release
are made as of the date of this press release. Neptune does not
undertake to update any such forward-looking statements whether as
a result of new information, future events or otherwise, except as
required by law. The forward-looking statements contained herein
are also subject generally to other risks and uncertainties that
are described from time to time in Neptune public securities
filings with the Securities and Exchange Commission and the
Canadian securities commissions. Additional information about these
assumptions and risks and uncertainties is contained in the AIF
under "Risk Factors".
Neither NASDAQ nor the Toronto Stock Exchange accepts
responsibility for the adequacy or accuracy of this release.
CONTACT: Neptune Contacts:
John Ripplinger
Investor Relations
+1.450.687.2262
j.ripplinger@neptunebiotech.com
neptunebiotech.com
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 6 2024 まで 7 2024
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 7 2023 まで 7 2024